Bromide

Bromide

SCHEMBL4031386

Br.Cc1ccc(C2CCCNC2)cc1O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC6A2 known ✓ P23975 1/20 0.49
SLC6A4 known ✓ P31645 1/20 0.49
SLC6A3 known ✓ Q01959 1/20 0.49
CYP2D6 P10635 1/20 0.49
KCNH2 Q12809 1/20 0.49
HTR2A P28223 2/20 0.47
DRD2 P14416 1/20 0.47
DRD3 P35462 1/20 0.47
QDPR P09417 1/20 0.46
NEK1 Q96PY6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27635029 0.98 CYP2D6 (0.50) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
Bromide SCHEMBL11720641 0.85 QDPR (0.64) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL11208701 0.83 QDPR (0.66) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL16736858 0.81 ACMSD (0.51) QDPR
SCHEMBL14300550 0.81 QDPR (0.49) CYP2D6QDPR
SCHEMBL31328458 0.80 QDPR (0.71) QDPR
SCHEMBL29890620 0.80 ACMSD (0.53) QDPR
SCHEMBL22313839 0.80 ACMSD (0.53) QDPR
SCHEMBL3357755 0.80 ACMSD (0.53) QDPR
SCHEMBL4032414 0.79 CYP2D6 (0.50) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567493-B1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PROD INC (US) 2009-03-18 EP disclosed
US-20070191429-A1 PPAR ACTIVATORS PFIZER INC. (US) 2007-08-16 US disclosed
US-7199243-B2 Piperidine compounds useful as PPAR activators PFIZER INC. (US) 2007-04-03 US disclosed
EP-1567493-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS Pfizer Products Inc. (US) 2005-08-31 EP disclosed
US-20040157885-A1 PPAR activators PFIZER INC 2004-08-12 US disclosed
WO-2004048334-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PRODUCTS INC. (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191429-A1 PPAR ACTIVATORS PPARA, PPARG, PPARD SLC6A2 4620/4885SLC6A4 4102/4885SLC6A3 4455/4885
US-20040157885-A1 PPAR activators PPARA, PPARG, PPARD SLC6A2 4620/4885SLC6A4 4102/4885SLC6A3 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.